Phase I Study of Cellular Immunotherapy for Recurrent/Refractory Malignant Glioma Using Intratumoral Infusions of GRm13Z40-2, An Allogeneic CD8+ Cytolitic T-Cell Line Genetically Modified to Express the IL 13-Zetakine and HyTK and to be Resistant to Glucocorticoids, in Combination With Interleukin-2 | MicrobiomeTrials
Phase I Study of Cellular Immunotherapy for Recurrent/Refractory Malignant Glioma Using Intratumoral Infusions of GRm13Z40-2, An Allogeneic CD8+ Cytolitic T-Cell Line Genetically Modified to Express the IL 13-Zetakine and HyTK and to be Resistant to Glucocorticoids, in Combination With Interleukin-2
CompletedPHASE1INTERVENTIONAL
Trial Details
Start: 2011-03-22Est. Completion: 2013-09-23
Enrollment target: 6 participants
Locations
City of Hope, Duarte, California, United States
Other microbiome trials you might be interested in
Grade II GliomaGrade III GliomaGrade IV GliomaAstrocytomaOligodendroglioma of BrainAnaplastic Astrocytoma of BrainAnaplastic OligodendrogliomaGlioblastoma
This pilot study will assess the safety and feasibility of using an implantable microdevice to measure local intratumor …